| Drug Name: | Probenecid (57-66-9) |
|---|---|
| PubChem ID: | 4911 |
| SMILES: | CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O |
| InchiKey: | DBABZHXKTCFAPX-UHFFFAOYSA-N |
| Therapeutic Category: | Adjuvants, Antirheumatic Agents, Gout Suppressants, Pharmaceutic Aids, Renal Agents, Uricosuric Agents |
| Molecular Weight (dalton) | : | 285.365 |
| LogP | : | 2.1955 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 74.68 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Cephalothin (153-61-7) | Nephrotoxicity | Antagonistic | Probenecid inhibits the excretion of most cephalosporins by the kidney tubules by successfully competing for the excretory mechanisms. Thus the cephalosporin is retained in the body and its serum levels rise. The extent of the rise cannot always be fully accounted for by this mechanism alone and it is suggested that some change in tissue distribution may sometimes have a part to play. | Probenecid: an unexplained effect on cephalosporin pharmacology |
| Cephaloridine (50-59-9) | Nephrotoxicity | Antagonistic | Probenecid inhibits the excretion of most cephalosporins by the kidney tubules by successfully competing for the excretory mechanisms. Thus the cephalosporin is retained in the body and its serum levels rise. The extent of the rise cannot always be fully accounted for by this mechanism alone and it is suggested that some change in tissue distribution may sometimes have a part to play. | Probenecid: an unexplained effect on cephalosporin pharmacology |
| Methotrexate (59-05-2) | Pancytopenia | Synergistic | Probenecid inhibits the renal excretion of methotrexate | Inhibition of renal tubular transport of methotrexate by probenecid |
| Ketorolac (66635-83-4) | Disorder Gastrointestinal | Antagonistic | Probenecid is a known substrate for renal glucuronidation, and possibly competitively inhibits the renal glucuronidation of these NSAIDs | Probenecid inhibits the glucuronidation of indomethacin and O-desmethylindomethacin in humans A pilot experiment |
| Pyrazinamide (98-96-4) | Diminished Uricosuric Effects Of Probenecid | Antagonistic | pyrazinamide additionally decreases the metabolism of the probenecid and prolongs its uricosuric effects | Studies of hyperuricemia produced by pyrazinamide |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cytotoxicity | Multidrug resistance-associated protein (P33527) | probenecid inhibites the activity of MDR-associated protein (MRP)@ thus increases the Cytotoxicity of doxorubicin [ ADR Type 4 ] | P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category